Venetoclax is a Bcl-2 antagonist that mimics the BH3 domain of pro-apoptotic Bcl-2 family members, thus antagonizing the anti-apoptotic Bcl-2 protein and enabling the activation of the effectors Bak and Bax on the mitochondrial surface of Bcl-2 dependent cancer cells. This evidence concerns the gene BCL2 and cancer.